Skip to main content
Erschienen in: Head and Neck Pathology 1/2022

21.03.2022 | UPDATE FROM THE 5TH EDITION OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF HEAD AND NECK TUMORS

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Familial Tumor Syndromes

verfasst von: Vania Nosé, Alexander J. Lazar

Erschienen in: Head and Neck Pathology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

The initiative of the 5th edition of the WHO classification of the Head and Neck Tumours establishing a new section dedicated to familial/heritable tumor syndromes with tumors and lesions in the head and neck region was much needed to better understand the tumours, diseases, and associated syndromes, as well as establish recommendations for monitoring and treating these patients. (WHO Classification of Tumours Editorial Board. Head and Neck tumours. Lyon (France): International Agency for Research on Cancer; 2022. https://​publications.​iarc.​fr/​). Within the newly established chapter on genetic tumor syndromes, we have described the main manifestations on the head and neck region in 15 syndromes. This review highlights the important findings within these syndromes, especially on the update on syndromes with tumors involving the head and neck region, as Gorlin syndrome/nevoid basal cell carcinoma syndrome associated with odontogenic keratocysts; Brooke-Spiegler syndrome/familial cylindromatosis and the associated membranous-type salivary gland basal cell adenoma, PTEN hamartoma tumor syndrome/Cowden syndrome with associated facial skin and mucosal lesions and characteristic multinodular thyroid lesions, Von Hippel Lindau syndrome and the associated middle ear endolymphatic sac tumor, as well as the fascinating genetic aspects of the diverse Head and Neck Paragangliomas. We will also discuss hyperparathyroidism-jaw tumor syndrome is characterized by parathyroid tumors in association with fibro-osseous jaw tumors, as well as head and neck desmoid tumors associated with familial adenomatous polyposis with Gardner syndrome variant familial, multicentric head and neck squamous cell carcinoma, tuberous sclerosis and neurofibromatosis type 1-associated head and neck lesions.
Literatur
1.
Zurück zum Zitat Howell JB, Caro MR. The basal-cell nevus: its relationship to multiple cutaneous cancers and associated anomalies of development. AMA Arch Dermatol. 1959;79(1):67–77 (discussion 77-80). Howell JB, Caro MR. The basal-cell nevus: its relationship to multiple cutaneous cancers and associated anomalies of development. AMA Arch Dermatol. 1959;79(1):67–77 (discussion 77-80).
2.
Zurück zum Zitat Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908–12.PubMed Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908–12.PubMed
3.
Zurück zum Zitat Evans DG, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30(6):460–4.PubMedPubMedCentral Evans DG, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30(6):460–4.PubMedPubMedCentral
4.
Zurück zum Zitat Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (Gorlin Syndrome). Head Neck Pathol. 2016;10(2):119–24.PubMedPubMedCentral Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (Gorlin Syndrome). Head Neck Pathol. 2016;10(2):119–24.PubMedPubMedCentral
5.
Zurück zum Zitat Stojanov IJ, et al. Biallelic PTCH1 inactivation is a dominant genomic change in sporadic keratocystic odontogenic tumors. Am J Surg Pathol. 2020;44(4):553–60.PubMedPubMedCentral Stojanov IJ, et al. Biallelic PTCH1 inactivation is a dominant genomic change in sporadic keratocystic odontogenic tumors. Am J Surg Pathol. 2020;44(4):553–60.PubMedPubMedCentral
6.
Zurück zum Zitat Foulkes WD, et al. Cancer surveillance in Gorlin syndrome and Rhabdoid tumor predisposition syndrome. Clin Cancer Res. 2017;23(12):e62–7.PubMedPubMedCentral Foulkes WD, et al. Cancer surveillance in Gorlin syndrome and Rhabdoid tumor predisposition syndrome. Clin Cancer Res. 2017;23(12):e62–7.PubMedPubMedCentral
7.
Zurück zum Zitat Karhade DS, Afshar S, Padwa BL. What is the prevalence of undiagnosed nevoid basal cell carcinoma syndrome in children with an odontogenic keratocyst? J Oral Maxillofac Surg. 2019;77(7):1389–91.PubMed Karhade DS, Afshar S, Padwa BL. What is the prevalence of undiagnosed nevoid basal cell carcinoma syndrome in children with an odontogenic keratocyst? J Oral Maxillofac Surg. 2019;77(7):1389–91.PubMed
8.
Zurück zum Zitat Li TJ. The odontogenic keratocyst: a cyst, or a cystic neoplasm? J Dent Res. 2011;90(2):133–42.PubMed Li TJ. The odontogenic keratocyst: a cyst, or a cystic neoplasm? J Dent Res. 2011;90(2):133–42.PubMed
9.
Zurück zum Zitat Qu J, et al. PTCH1 alterations are frequent but other genetic alterations are rare in sporadic odontogenic keratocysts. Oral Dis. 2019;25(6):1600–7.PubMed Qu J, et al. PTCH1 alterations are frequent but other genetic alterations are rare in sporadic odontogenic keratocysts. Oral Dis. 2019;25(6):1600–7.PubMed
10.
Zurück zum Zitat Robinson RA. Basal cell adenoma and basal cell adenocarcinoma. Surg Pathol Clin. 2021;14(1):25–42.PubMed Robinson RA. Basal cell adenoma and basal cell adenocarcinoma. Surg Pathol Clin. 2021;14(1):25–42.PubMed
11.
Zurück zum Zitat Rito M, et al. Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression. Mod Pathol. 2018;31(7):1064–72.PubMed Rito M, et al. Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression. Mod Pathol. 2018;31(7):1064–72.PubMed
12.
Zurück zum Zitat Nagao T, et al. Carcinoma in basal cell adenoma of the parotid gland. Pathol Res Pract. 1997;193(3):171–8.PubMed Nagao T, et al. Carcinoma in basal cell adenoma of the parotid gland. Pathol Res Pract. 1997;193(3):171–8.PubMed
13.
Zurück zum Zitat Nose V. Genodermatosis affecting the skin and mucosa of the head and neck: clinicopathologic, genetic, and molecular aspect–PTEN-hamartoma tumor syndrome/cowden syndrome. Head Neck Pathol. 2016;10(2):131–8.PubMedPubMedCentral Nose V. Genodermatosis affecting the skin and mucosa of the head and neck: clinicopathologic, genetic, and molecular aspect–PTEN-hamartoma tumor syndrome/cowden syndrome. Head Neck Pathol. 2016;10(2):131–8.PubMedPubMedCentral
14.
Zurück zum Zitat Laury AR, et al. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid. 2011;21(2):135–44.PubMed Laury AR, et al. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid. 2011;21(2):135–44.PubMed
15.
Zurück zum Zitat Bausch B, et al. Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry. Head Neck. 2016;38(Suppl 1):E673–9.PubMed Bausch B, et al. Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry. Head Neck. 2016;38(Suppl 1):E673–9.PubMed
16.
Zurück zum Zitat Codreanu CM, et al. Endolymphatic sac tumors in von Hippel-Lindau disease: report of three cases. Otol Neurotol. 2010;31(4):660–4.PubMed Codreanu CM, et al. Endolymphatic sac tumors in von Hippel-Lindau disease: report of three cases. Otol Neurotol. 2010;31(4):660–4.PubMed
17.
Zurück zum Zitat Codreanu C, Tran Ba Huy P. Isolate vertigo crisis revealing an endolymphatic sac tumor. Rom J Morphol Embryol. 2010;51(2):387–9.PubMed Codreanu C, Tran Ba Huy P. Isolate vertigo crisis revealing an endolymphatic sac tumor. Rom J Morphol Embryol. 2010;51(2):387–9.PubMed
18.
Zurück zum Zitat Wick CC, et al. Endolymphatic sac tumors. Otolaryngol Clin North Am. 2015;48(2):317–30.PubMed Wick CC, et al. Endolymphatic sac tumors. Otolaryngol Clin North Am. 2015;48(2):317–30.PubMed
19.
Zurück zum Zitat Vortmeyer AO, et al. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol. 2013;125(3):333–50.PubMed Vortmeyer AO, et al. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol. 2013;125(3):333–50.PubMed
20.
Zurück zum Zitat Wanebo JE, et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82–94.PubMed Wanebo JE, et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82–94.PubMed
21.
Zurück zum Zitat Binderup MLM, et al. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol. 2018;102(7):942–7.PubMed Binderup MLM, et al. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol. 2018;102(7):942–7.PubMed
24.
Zurück zum Zitat Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin A clinicopathologic study of 20 cases. Cancer. 1989;64(11):2292–302.PubMed Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin A clinicopathologic study of 20 cases. Cancer. 1989;64(11):2292–302.PubMed
25.
Zurück zum Zitat el-Naggar AK, et al. Tumors of the middle ear and endolymphatic sac. Pathol Annu. 1994;29(Pt 2):199–231.PubMed el-Naggar AK, et al. Tumors of the middle ear and endolymphatic sac. Pathol Annu. 1994;29(Pt 2):199–231.PubMed
26.
Zurück zum Zitat Bisceglia M, D’Angelo VA, Wenig BM. Endolymphatic sac papillary tumor (Heffner tumor). Adv Anat Pathol. 2006;13(3):131–8.PubMed Bisceglia M, D’Angelo VA, Wenig BM. Endolymphatic sac papillary tumor (Heffner tumor). Adv Anat Pathol. 2006;13(3):131–8.PubMed
27.
Zurück zum Zitat Skalova A, et al. Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): report of two cases with analysis of the VHL gene. Pathol Res Pract. 2008;204(8):599–606.PubMed Skalova A, et al. Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): report of two cases with analysis of the VHL gene. Pathol Res Pract. 2008;204(8):599–606.PubMed
29.
Zurück zum Zitat Bell D, et al. Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience. Ann Diagn Pathol. 2011;15(2):117–23.PubMed Bell D, et al. Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience. Ann Diagn Pathol. 2011;15(2):117–23.PubMed
30.
Zurück zum Zitat Thompson LDR, et al. CAIX and pax-8 commonly immunoreactive in endolymphatic sac tumors: a clinicopathologic study of 26 cases with differential considerations for metastatic renal cell carcinoma in von hippel-lindau patients. Head Neck Pathol. 2019;13(3):355–63.PubMed Thompson LDR, et al. CAIX and pax-8 commonly immunoreactive in endolymphatic sac tumors: a clinicopathologic study of 26 cases with differential considerations for metastatic renal cell carcinoma in von hippel-lindau patients. Head Neck Pathol. 2019;13(3):355–63.PubMed
31.
Zurück zum Zitat Smith JD, et al. Head and neck paragangliomas: a two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol. 2017;2(6):380–9.PubMedPubMedCentral Smith JD, et al. Head and neck paragangliomas: a two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol. 2017;2(6):380–9.PubMedPubMedCentral
32.
Zurück zum Zitat Kriegsmann K, et al. Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl Immunohistochem Mol Morphol. 2020;28(3):237–42.PubMed Kriegsmann K, et al. Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl Immunohistochem Mol Morphol. 2020;28(3):237–42.PubMed
33.
Zurück zum Zitat Juhlin CC, Zedenius J, Hoog A. Clinical routine application of the second-generation neuroendocrine markers ISL1, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin. Endocr Pathol. 2020;31(4):401–10.PubMedPubMedCentral Juhlin CC, Zedenius J, Hoog A. Clinical routine application of the second-generation neuroendocrine markers ISL1, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin. Endocr Pathol. 2020;31(4):401–10.PubMedPubMedCentral
34.
Zurück zum Zitat Pinato DJ, et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108(2):429–37.PubMed Pinato DJ, et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108(2):429–37.PubMed
35.
Zurück zum Zitat Favier J, et al. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Mod Pathol. 2020;33(1):57–64.PubMed Favier J, et al. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Mod Pathol. 2020;33(1):57–64.PubMed
36.
Zurück zum Zitat Kimura N, et al. Familial cervical paragangliomas with lymph node metastasis expressing somatostatin receptor type 2A. Endocr Pathol. 2010;21(2):139–43.PubMed Kimura N, et al. Familial cervical paragangliomas with lymph node metastasis expressing somatostatin receptor type 2A. Endocr Pathol. 2010;21(2):139–43.PubMed
37.
Zurück zum Zitat Amar L, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435–44.PubMedPubMedCentral Amar L, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435–44.PubMedPubMedCentral
38.
Zurück zum Zitat McCrary HC, et al. Characterization of malignant head and neck paragangliomas at a single institution across multiple decades. JAMA Otolaryngol Head Neck Surg. 2019;145(7):641–6.PubMedPubMedCentral McCrary HC, et al. Characterization of malignant head and neck paragangliomas at a single institution across multiple decades. JAMA Otolaryngol Head Neck Surg. 2019;145(7):641–6.PubMedPubMedCentral
39.
Zurück zum Zitat Bouaoun L, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37(9):865–76.PubMed Bouaoun L, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37(9):865–76.PubMed
40.
Zurück zum Zitat Prime SS, et al. A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol. 2001;37(1):1–16.PubMed Prime SS, et al. A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol. 2001;37(1):1–16.PubMed
41.
Zurück zum Zitat Scheckenbach K, et al. Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines. Klin Padiatr. 2012;224(3):132–8.PubMed Scheckenbach K, et al. Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines. Klin Padiatr. 2012;224(3):132–8.PubMed
42.
Zurück zum Zitat Saito Y, et al. Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Ann Surg Oncol. 2016;23(Suppl 4):559–65.PubMed Saito Y, et al. Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Ann Surg Oncol. 2016;23(Suppl 4):559–65.PubMed
43.
Zurück zum Zitat Lee BD, et al. A case report of Gardner syndrome with hereditary widespread osteomatous jaw lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2009;107(3):e68-72. Lee BD, et al. A case report of Gardner syndrome with hereditary widespread osteomatous jaw lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2009;107(3):e68-72.
45.
Zurück zum Zitat Boyraz B, et al. Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol. 2021;32(3):327–35.PubMed Boyraz B, et al. Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol. 2021;32(3):327–35.PubMed
46.
Zurück zum Zitat Carpenter TO, et al. Case 32–2021: a 14-year-old girl with swelling of the jaw and hypercalcemia. N Engl J Med. 2021;385(17):1604–13.PubMed Carpenter TO, et al. Case 32–2021: a 14-year-old girl with swelling of the jaw and hypercalcemia. N Engl J Med. 2021;385(17):1604–13.PubMed
47.
Zurück zum Zitat Nguyen QD, DarConte MD, Hebert AA. The cutaneous manifestations of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):321–5.PubMed Nguyen QD, DarConte MD, Hebert AA. The cutaneous manifestations of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):321–5.PubMed
48.
Zurück zum Zitat Bree AF, Shah MR, for the BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet Part A. 2011;155:2091–7. Bree AF, Shah MR, for the BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet Part A. 2011;155:2091–7.
49.
Zurück zum Zitat Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16.PubMed Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16.PubMed
Metadaten
Titel
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Familial Tumor Syndromes
verfasst von
Vania Nosé
Alexander J. Lazar
Publikationsdatum
21.03.2022
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 1/2022
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-022-01414-z

Weitere Artikel der Ausgabe 1/2022

Head and Neck Pathology 1/2022 Zur Ausgabe

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumours of the Ear

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …